2026年11月3日星期二
M
विश्व व्यापक संदर्भ
वैश्विक ताज़ा ख़बरें
Working collaboratively to fight scams in Asia Pacific— Google 官方博客Japan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaWorking collaboratively to fight scams in Asia Pacific— Google 官方博客Japan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei Asia

Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS)

स्रोत Nature 医学研究1 दिन पहले
सामग्री सारांश

यह साइट केवल शीर्षक और सारांश सूचकांक प्रदान करती है, पूरी सामग्री और कॉपीराइट मूल प्रकाशक के पास हैं, कृपया मूल लिंक पर क्लिक करके पढ़ें।

मूल पाठ पर जाएं
संबंधित चैनल
स्वास्थ्य
संबंधित क्षेत्र
वैश्विक दृष्टिकोण
मूल भाषा
English
प्रविष्टि संख्या
health-39a0fe5c

Comments 0 comments

No comments yet. Be the first.

Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS) · विश्व व्यापक संदर्भ